The major updates in the 2016 WHO classification for Philadelphia-negative MPN aimed at distinguishing between masked PV and JAK2-mutated ET, and between prefibrotic and overtly fibrotic PMF. This evidence concerns the gene JAK2 and essential thrombocythemia.